Sponsored Link:

Global Investing Roundups

Oil Continues Slide; FDA Blocks Ranbaxy, Best Buy Profit Declines; Bristol-Myers Bid Uncertain; Pandit’s Reassuring Memo; GM Showcases the Volt; Adobe Beats the Street; Constellation Plunges on Debt Worries

  • Oil prices extended their decline yesterday (Tuesday), falling $10 a barrel in a dramatic, two-day slide as the outlook for U.S., as well as global, energy demand grew weaker. Light, sweet crude for October delivery fell $4.56 to settle at $91.15 a barrel on the New York Mercantile Exchange, after earlier falling as low as $90.51 – the lowest level since Feb. 8.
  • The Food and Drug Administration is closing U.S. borders to more than 30 generic drugs made by India’s Ranbaxy Laboratories Ltd. (OTC: RBXLY), citing poor quality in two of the company’s factories, The Associated Press reported.  However, Ranbaxy can continue selling medicines made at any of its other factories.
  • Best Buy Co. (BBY) said yesterday (Tuesday) that its second-quarter profit fell 19%, to $202 million, despite a 12% jump in revenue.  Same-store sales jumped 4.2% and total revenue came in at $9.8 billion. A sluggish U.S. economy will continue to challenge the retail giant the second half of the year.
  • Bristol-Myers Squibb Co. (BMY) said yesterday (Tuesday) that it might drop its $4.5 billion offer for the 83% of ImClone Systems Inc. (IMCL) it doesn’t already own. "There are situations in which we are willing, and we’ve disclosed that, we’re willing to walk away," Jean-Marc Huet, Bristol’s Chief Financial Officer, said response to a question at a pharmaceutical investors conference, The Associated Press reported.


September 17th, 2008

Why Gold Will Surpass $2,500

Few investors realize that inflation is the least of the factors driving the bull market in gold. Other factors, like Venezuela's crackdown on gold exports, are likely to push prices higher. Find out how to play each of the "7 Key Drivers" in our Money Morning Publisher's Series report... Go here to get it for free.




Post a Response